Description
AOD-9604 (also known as AOD9604, Tyr-somatostatin (177–191), or hGH fragment 177–191) is a modified peptide fragment derived from the C-terminus of human growth hormone. It retains the lipolytic (fat-breaking) properties of full-length hGH while lacking its growth-promoting and glucose-modulating effects. The peptide contains a disulfide bridge between cysteine residues at positions 7 and 14, which is essential for its biological activity.
This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.
Key Research Focus
AOD-9604 has been the subject of extensive preclinical and clinical research exploring its metabolic properties:
- Lipolysis and Fat Oxidation: In obese (ob/ob) mice, chronic AOD-9604 treatment (250 µg/kg/day) significantly reduced body weight gain, epididymal adipose tissue mass, and brown adipose tissue weight. These effects were associated with increased in vivo fat oxidation and elevated plasma glycerol levels, an index of lipolysis. Unlike full-length growth hormone, AOD-9604 did not induce hyperglycaemia or reduce insulin secretion.
- Mechanism of Action: AOD-9604 does not compete for the growth hormone receptor and does not induce cell proliferation, distinguishing its mechanism from traditional hGH-stimulated pathways. Research has shown that AOD-9604 increases expression of beta(3)-adrenergic receptor (β3-AR) RNA in obese mice to levels comparable to lean controls. However, the lipolytic effects of AOD-9604 are not mediated directly through β3-AR, as acute treatment increased energy expenditure and fat oxidation even in β3-AR knockout mice.
- Metabolic Profile: Preclinical studies demonstrate that AOD-9604 has a GH-sparing profile: it lacks the IGF-1 elevation and insulin resistance effects associated with full human growth hormone protocols. This makes it a valuable research tool for isolating lipolytic mechanisms from GH-receptor-mediated pathways.
- Cartilage and Joint Research: AOD-9604 has also been investigated for its potential effects on cartilage regeneration. In a rabbit model of collagenase-induced knee osteoarthritis, intra-articular injection of AOD-9604 (with or without hyaluronic acid) enhanced cartilage regeneration.
- Human Safety Data: Six randomized, double-blind, placebo-controlled clinical studies have evaluated the safety and tolerability of AOD-9604 in humans via intravenous and oral routes. In these studies, adverse events were generally mild to moderate and similarly distributed between AOD-9604 and placebo groups. Commonly reported events included headache, fatigue, and dizziness. No serious adverse events were reported.
Product Specifications
- Form: Lyophilized Powder (Sterile)
- Purity: ≥95–98% (HPLC Verified)
- Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂ (free base)
- Molecular Weight: 1815.10 (free base); 1875.13 (acetate)
- CAS Number: 221231-10-3
- Sequence: YLRIVQCRSVEGSCGF (Disulfide bond Cys7–Cys14)
- Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
- Solubility: Slightly soluble in DMSO; may be reconstituted with Bacteriostatic Water for laboratory use.
- Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use. AOD-9604 is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under section S2.2 (Peptide Hormones, Growth Factors, and Related Substances).
Why Choose AOD-9604?
AOD-9604 is a mechanistically distinct research tool for studying lipolysis and energy metabolism. Unlike full-length growth hormone, it selectively activates fat oxidation pathways without engaging the GH receptor or elevating IGF-1, making it valuable for researchers seeking to isolate lipolytic mechanisms from broader GH signaling. Its well-documented preclinical profile—including reduced adiposity, enhanced fat oxidation, and β3-AR modulation—provides a solid foundation for metabolic research. Additionally, the availability of human safety data from early-phase clinical trials offers researchers a comparative reference point for understanding its tolerability profile.



